CoChat
Sign Up
Cited by 69Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and MetabolismCardiovascular Disease and Adiposity

The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.

Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases

Open access
Liu, Ying, Vu, Vivian, Sweeney, Gary·2019·Frontiers in Endocrinology
DOI 10.3389/fendo.2019.00842PMC PMC6918867
Open this paper in CoChat — free accountOpen PDF

Abstract

Cardiometabolic diseases encompass those affecting the heart and vasculature as well as other metabolic problems, such as insulin resistance, diabetes, and non-alcoholic fatty liver disease. These diseases tend to have common risk factors, one of which is impaired adiponectin action. This may be due to reduced bioavailability of the hormone or resistance to its effects on target tissues. A strong negative correlation between adiponectin levels and cardiometabolic diseases has been well-documented and research shown that adiponectin has cardioprotective, insulin sensitizing and direct beneficial metabolic effects. Thus, therapeutic approaches to enhance adiponectin action are widely considered to be desirable. The complexity of adiponectin structure and function has so far made progress in this area less than ideal. In this article we will review the effects and mechanism of action of adiponectin on cardiometabolic tissues, identify scenarios where enhancing adiponectin action would be of clinical value and finally discuss approaches via which this can be achieved.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2019.00842

Cites

222 of 222 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Interventions that enhance adiponectin receptor expression. Adiponectin receptor expression can be increased by lifestyle interventions, such as diet and exercise as well as through pharmacological therapies as shown.
Figure 1 Interventions that enhance adiponectin receptor expression. Adiponectin receptor expression can be increased by lifestyle interventions, such as diet and exercise as well as through pharmacological therapies as shown.CC BY · PubMed Central
Figure 2 Adiponectin receptor agonists. Binding of full-length and globular adiponectin to adiponectin receptors with seven transmembrane spanning domains (left side) normally activates downstream signaling pathways, such as AMPK, p38MAPK, and PPAR-alpha. Multiple adiponectin receptor agonists have now been identified to also bind adiponectin receptors and induce these downstream signaling cascades.
Figure 2 Adiponectin receptor agonists. Binding of full-length and globular adiponectin to adiponectin receptors with seven transmembrane spanning domains (left side) normally activates downstream signaling pathways, such as AMPK, p38MAPK, and PPAR-alpha. Multiple adiponectin receptor agonists have now been identified to also bind adiponectin receptors and induce these downstream signaling cascades.CC BY · PubMed Central
Figure 3 Enhanced adiponectin therapeutics via precision medicine upon personalized response prediction. Accumulation of big data will allow algorithm-based prediction of those individuals most likely to benefit from therapeutic agents to either increase adiponectin levels or directly mimic adiponectin action, thus resulting in more efficient and improved health care outcomes.
Figure 3 Enhanced adiponectin therapeutics via precision medicine upon personalized response prediction. Accumulation of big data will allow algorithm-based prediction of those individuals most likely to benefit from therapeutic agents to either increase adiponectin levels or directly mimic adiponectin action, thus resulting in more efficient and improved health care outcomes.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 69

Related

See all

Metadata

Authors
Liu, Y., Vu, V., & Sweeney, G.
Affiliations
York University (CA)
Corresponding author
  • Liu, Ying
  • Sweeney, Gary
ORCID
Venue
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Published
2019-12-11
Volume
10
Pages
842-842
ISSN
1664-2392 (ISSN-L)
DOI
10.3389/fendo.2019.00842
PMC
PMC6918867
OpenAlex
W2995030404
Cited by
69
References
222
Citations by year
2026: 5 · 2025: 6 · 2024: 12 · 2023: 14 · 2022: 8 · 2021: 15 · 2020: 7
FWCI
1.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
adiponectin, cardiometabolic disease, insulin resistance, diabetes mellitus, non-alcoholic fatty liver disease, adiponectin resistance, cardioprotection, insulin sensitization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review